CAR T Cell Generation From Cryopreserved Leukapheresis Products In A 7-Day Process

CAR T cell therapies continue to advance, but manufacturing speed, flexibility, and logistics remain persistent hurdles. Explore a streamlined, seven‑day approach to generating functional CAR T cells starting from cryopreserved leukapheresis material. Using an integrated, automated workflow, CD4⁺ and CD8⁺ T cells are enriched, activated, transduced, expanded, and harvested while maintaining high viability and consistent expansion. Two CAR constructs—CD19 and CD19/CD22 tandem—demonstrated comparable transduction efficiency, stable vector copy numbers, and robust cytokine secretion. Functional potency was confirmed through both in vitro cytotoxicity assays and in vivo tumor clearance models. By demonstrating reliable CAR T cell generation from frozen starting material within a shortened timeline, this work highlights a practical path toward reducing logistical complexity, improving scalability, and supporting more flexible manufacturing strategies for gene‑engineered cell therapies.

Access the full application note to explore the data behind this approach.